498 related articles for article (PubMed ID: 10541378)
1. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
2. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
3. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
4. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
8. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
9. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
[TBL] [Abstract][Full Text] [Related]
12. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
[TBL] [Abstract][Full Text] [Related]
14. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
17. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
[TBL] [Abstract][Full Text] [Related]
20. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
